| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Recission of common stock | - | 0 |
| Net cash provided by financing activities | 27,317,000 | 625,000 |
| Net increase in cash and cash equivalents | 13,740,000 | -454,271 |
| Cash and cash equivalents at beginning of period | 513,000 | - |
| Cash and cash equivalents at end of period | 14,253,000 | - |
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)